Dr. Bruix Discusses the Success of Regorafenib in HCC

Jordi Bruix, MD
Published: Saturday, Apr 22, 2017



Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

Since sorafenib (Nexavar) was approved for treatment of patients with advanced HCC in 2007, there has been little to no success in trials of second-line treatments.

RESOURCE, a phase III randomized study of regorafenib in the second-line setting, showed a very significant improvement in survival. Bruix, the lead author of the study, says that these results have lifted the morale of the field from its previously discouraged state.
 


Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

Since sorafenib (Nexavar) was approved for treatment of patients with advanced HCC in 2007, there has been little to no success in trials of second-line treatments.

RESOURCE, a phase III randomized study of regorafenib in the second-line setting, showed a very significant improvement in survival. Bruix, the lead author of the study, says that these results have lifted the morale of the field from its previously discouraged state.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x